Optiscan Lodges U.S. FDA 510(k) Submission for InForm
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Optiscan Imaging Limited has lodged a submission with the U.S. FDA for its InForm digital pathology device, marking a significant step towards commercialization in the U.S. market. This submission is a crucial part of the regulatory approval process, demonstrating the device's safety and performance. As the device progresses through the FDA review, Optiscan will continue to engage with clinical partners and build its evidence base. The CEO emphasized that this milestone reflects the company's enhanced capabilities and readiness for future regulatory submissions.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Optiscan Imaging Limited on 6ix
Story so far
Earlier from Optiscan Imaging
- Change of Director's Interest Notice
- Notification of cessation of securities - OIL
- Application for quotation of securities - OIL
- Significant Milestone Reached in ACL Digital Pathology Study
- Optiscan Initiates Head and Neck Cancer Study in the US
Later from Optiscan Imaging
- Optiscan Lodges U.S. FDA 510(k) Submission for InVue
- Quarterly Activities/Appendix 4C Cash Flow Report
- Optiscan Strengthens Board with Appointment of Russell Low
Follow Optiscan Imaging into a list and get an email when it puts out news.
Follow Optiscan Imaging